Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies

被引：28
|
作者：
Page, M. M. [1 ]
Ekinci, E. I. [2 ,4 ,5 ]
Jones, R. M. [3 ,4 ]
Angus, P. W. [3 ,4 ]
Gow, P. J. [3 ,4 ]
O'Brien, R. C. [2 ,4 ]
机构：
[1] Royal Perth Hosp, Lipid Disorders Clin, Perth, WA 6000, Australia
[2] Austin Hlth, Austin Hlth Endocrine Ctr, Melbourne, Vic, Australia
[3] Austin Hlth, Liver Transplant Unit, Melbourne, Vic, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[5] Menzies Sch Hlth Res, Darwin, NT, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2014年 / 44卷 / 06期
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
familial hypercholesterolaemia; liver transplantation; LDL-apheresis; mipomersen; lomitapide; HEART; LIPOPROTEINS; SURGERY; PATIENT; BYPASS;
D O I：
10.1111/imj.12444
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Homozygous familial hypercholesterolaemia (FH) causes severe premature coronary artery disease because of very high levels of low density lipoprotein (LDL)-cholesterol. Standard lipid-lowering drugs and LDL-apheresis may not be sufficiently effective. Liver transplantation replaces defective LDL receptors and vastly improves the lipid profile, and we present the first report of an Australian adult to receive this treatment. Emerging drug treatments for FH may be alternatives to LDL-apheresis and transplantation, but long-term safety and efficacy data are lacking for all of these options.
引用
收藏
页码：601 / 604
页数：4
相关论文
共 50 条
  • [21] TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH LIPID-LOWERING DRUGS
    ILLINGWORTH, DR
    BACON, S
    ARTERIOSCLEROSIS, 1989, 9 (01): : I121 - I134
  • [22] Plant sterol supplementation on top of lipid-lowering therapies in familial hypercholesterolemia
    Machado, Valeria A.
    Fonseca, Francisco A.
    Fonseca, Henrique A.
    Malina, Daniela T.
    Fonzar, Waleria T.
    Barbosa, Silvio A.
    Santana, Jose M.
    Izar, Maria C.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 184 : 570 - 572
  • [23] Comorbidity in lipoprotein apheresis: Their role in the era of new lipid-lowering therapies
    Sbrana, Francesco
    Pianelli, Mascia
    Luciani, Roberta
    Bigazzi, Federico
    Corciulo, Carmen
    Ripoli, Andrea
    Sampietro, Tiziana
    Dal Pino, Beatrice
    JOURNAL OF CLINICAL APHERESIS, 2024, 39 (01)
  • [24] Is there a role of lipid-lowering therapies in the management of fatty liver disease?
    Ismini Tzanaki
    Aris P Agouridis
    Michael S Kostapanos
    World Journal of Hepatology, 2022, 14 (01) : 119 - 139
  • [25] Is there a role of lipid-lowering therapies in the management of fatty liver disease?
    Tzanaki, Ismini
    Agouridis, Aris P.
    Kostapanos, Michael S.
    WORLD JOURNAL OF HEPATOLOGY, 2022, 14 (01) : 119 - 139
  • [26] Evolocumab for the treatment of homozygous familial hypercholesterolaemia
    Blom, Dirk Jacobus
    Marais, A. David
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (07): : 789 - 798
  • [27] Treatment of children with homozygous familial hypercholesterolaemia
    Reiner, Zeljko
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2018, 25 (10) : 1095 - 1097
  • [28] Crude Ethanol Extract of Pithecellobium ellipticum as a Potential Lipid-Lowering Treatment for Hypercholesterolaemia
    Wong, Janet P. -C.
    Wijaya, Sumi
    Ting, Kang-Nee
    Wiart, Christophe
    Mustafa, Kamarul'Ain
    Shipton, Fiona
    Khoo, Teng-Jin
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [29] Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
    Raal, Frederick J.
    Pilcher, Gillian J.
    Panz, Vanessa R.
    van Deventer, Hendrick E.
    Brice, Brigitte C.
    Blom, Dirk J.
    Marais, A. David
    CIRCULATION, 2011, 124 (20) : 2202 - 2207
  • [30] Comparative effects of lipid-lowering therapies
    Davidson, MH
    Toth, PP
    PROGRESS IN CARDIOVASCULAR DISEASES, 2004, 47 (02) : 73 - 104
12345